Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Holding RARE?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.34Last Year’s EPS
-1.52Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: -23.34%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth and significant advancements in clinical programs, particularly in gene therapy and commercialization efforts. However, high operating expenses and ongoing cash burn remain challenges.Company Guidance
In the Ultragenyx Q3 2024 earnings call, the company provided guidance highlighting several key metrics and strategic advancements. The company reported $139 million in total revenue for the quarter, marking a 42% increase year-over-year. Crysvita contributed $98 million, Dojolvi added $21 million, Evkeeza brought in $11 million, and Mepsevii accounted for $10 million. The operating expenses totaled $271 million, with a net loss of $134 million or $1.40 per share. As of September 30, 2024, Ultragenyx had $825 million in cash, cash equivalents, and marketable securities. Looking ahead, the company reaffirmed its 2024 revenue guidance range of $530 million to $550 million, with Crysvita expected to be towards the upper end of its range, and Dojolvi revenue projected between $75 million and $80 million. This guidance reflects confidence in their growing global portfolio and strategic initiatives, including potential near-term approvals for treatments targeting Sanfilippo syndrome, GSDIa, and osteogenesis imperfecta.Significant Revenue Growth
Ultragenyx reported $139 million in total revenue for Q3 2024, representing a 42% growth compared to the prior year quarter.
Strong Performance of Crysvita
Crysvita contributed $98 million in revenue, with notable sales in North America, Latin America, Turkey, and Europe.
Breakthrough Therapy Designation for UX143
UX143 for osteogenesis imperfecta received breakthrough therapy designation from the FDA to reduce fracture risk in patients aged 2 and older.
Progress in Gene Therapy Programs
New data from DTX401 for glycogen storage disease type 1a showed a 62% mean reduction in daily cornstarch requirement in crossover patients.
Successful Commercialization Efforts
Generated over $110 million in revenue in Latin America this year, with significant contributions from Crysvita, Mepsevii, Dojolvi, and Evkeeza.
---
RARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $52.18 | $50.52 | -3.18% |
| Aug 01, 2024 | $44.15 | $50.47 | +14.31% |
| May 02, 2024 | $43.20 | $42.75 | -1.04% |
| Feb 15, 2024 | $46.26 | $48.92 | +5.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ultragenyx Pharmaceutical (RARE) report earnings?
Ultragenyx Pharmaceutical (RARE) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Ultragenyx Pharmaceutical (RARE) earnings time?
Ultragenyx Pharmaceutical (RARE) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RARE EPS forecast?
RARE EPS forecast for the fiscal quarter 2024 (Q4) is -1.34.
---